Brainstorm Cell Ownership
| GHDN Stock | EUR 2.69 0.00 0.00% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Brainstorm |
Brainstorm Stock Ownership Analysis
About 23.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.68. Brainstorm Cell Ther had not issued any dividends in recent years. The entity had 15:1 split on the 31st of August 2024. Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York. BRAINSTORM operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 31 people. To learn more about Brainstorm Cell Therapeutics call Chaim Lebovits at 201 488 0460 or check out https://www.brainstorm-cell.com.Brainstorm Cell Outstanding Bonds
Brainstorm Cell issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Brainstorm Cell Ther uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Brainstorm bonds can be classified according to their maturity, which is the date when Brainstorm Cell Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Brainstorm Stock
When determining whether Brainstorm Cell Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Brainstorm Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Brainstorm Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Brainstorm Cell Therapeutics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Brainstorm Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.